Absence of nuclear factor kappaB inhibition by NSAIDs in hepatocytes (Q28192297)

1

0 references

Marta Casado

2

0 references

Lisardo Boscá

3

0 references

Paloma Martín-Sanz

Prostaglandin endoperoxide synthase: regulation of enzyme expression

4

0 references

language of work or name

English

0 references

publication date

February 2002

0 references

published in

Hepatology

0 references

volume

35

0 references

issue

2

0 references

page(s)

341-8

0 references

cites work

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

The role of cyclooxygenases in inflammation, cancer, and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Aspirin use and reduced risk of fatal colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Glucagon-induced changes in fructose 2,6-bisphosphate and 6-phosphofructo-2-kinase in cultured rat foetal hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Expression of cyclooxygenase-2 in foetal rat hepatocytes stimulated with lipopolysaccharide and pro-inflammatory cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-Delta(12,14)-prostaglandin J(2) in activated murine macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Regulation of cyclooxygenase 2 expression in hepatocytes by CCAAT/enhancer-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Aspirin induces cell death and caspase-dependent phosphatidylserine externalization in HT-29 human colon adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Cyclooxygenases: structural, cellular, and molecular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

The NF-kappa B and I kappa B proteins: new discoveries and insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

The IKK complex: an integrator of all signals that activate NF-kappaB?

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163

In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31163